

tbri



IMMUNE HEALTH
RESEARCH

Biogram
TAMPA BAY RESEARCH INSTITUTE

A NOT-FOR-PROFIT ORGANIZATION DEDICATED TO BIOMEDICAL RESEARCH

**YOU AND YOUR GUESTS
ARE INVITED TO
TBRI'S ANNUAL COMMUNITY RECEPTION**

DATE: WEDNESDAY, OCT. 21, 2009

TIME: 6:00 PM

LOCATION:

HILTON ST. PETERSBURG
CARILLON PARK, 950 LAKE CARILLON DRIVE
ST. PETERSBURG, FLORIDA 33716
PH (727) 540-0050

PLEASE RESPOND TO: 727-576-6675 EXT. 123
DTIPPINS@TAMPABAYRESEARCH.ORG

KEYNOTE ADDRESS

G. YANCEY GILLESPIE, PH.D.

DIRECTOR, BRAIN TUMOR SPORE PROGRAM
PROFESSOR OF SURGERY, MICROBIOLOGY & CELL BIOLOGY
UNIVERSITY OF ALABAMA AT BIRMINGHAM

**"CHALLENGES OF UNDERSTANDING AND TREATING
MALIGNANT BRAIN TUMORS: FACT, FANCY AND FUTURE"**

W. GUY BRADLEY, PH.D.

PRINCIPAL INVESTIGATOR, TAMPA BAY RESEARCH INSTITUTE

TBRI RESEARCH UPDATE

THANK YOU

to our Community Reception Sponsors!

Rothman Family Foundation

Bay Cities Bank

Jerry & Jewel Curley

Cliff Hardy & Judy Morris-Hardy

Andrew H. Hines, Jr.

Peter & Mary Lee Jones

John & Sandy Kearney

Joshua T. Keleske, P.A.

Trusted Counsel Of Tampa Bay

Dorothy Knab, Ph.D.

Douglas Knab, M.D.

Raymond James & Associates

Randy & Martha Loyd

Byron & Andrea Smith

Mary E. Smith, D.V.M.

Akiko Tanaka, Ph.D.

Dick & Shawn Ulrich

Unlimited Printing & Copying

Woody & Dee Weidemeyer

*Sponsors at the time of this printing.
Please contact TBRI to become an event sponsor.*

Dr. Gillespie's research is focused on developing and testing therapies for the treatment of malignant brain tumors in adults and children. He has been working on gene transfer techniques, including the use of certain types of herpes simplex viruses that can function as therapies against certain types of brain cancer. Innovative work such as this complements TBRI's mission, which includes the development of novel anti-cancer therapies.

HIS MANY ACHIEVEMENTS INCLUDE:

- *The use of high field strength magnetic resonance imaging to detect and monitor tumor growth in transgenic mice;*
- *Publication of over 160 peer-reviewed research articles;*
- *Conducting several clinical trials of anti-cancer compounds;*
- *Director, University of Alabama at Birmingham Specialized Program of Research Excellence in Neurological Cancer; and*
- *Recipient of the National Cancer Institute's Research Service Award.*

**FALL 2009
TABLE OF CONTENTS**

Dr. Gillespie	1
Chairman's Message	2
In The Lab	2
Introducing New Board Members	3
A Charitable Gift	3
CELL-ebrations of Life	4



Chairman's Message

Judy Morris-Hardy

The August 30, 2009 issue of the magazine *Parade* featured an article titled "Will Medical Research Change Your Life?" Scientists and supporters of Tampa Bay Research Institute know the answer to that question is a resounding "yes!"

The more publicized aspects about this summer's heated health care debate were mainly about costs and coverage.

What has not received much publicity are the following facts pointed out in the article:

- *Many people are still alive because of basic science.*
- *After doubling from 1998 to 2003, the amount of money Congress appropriated to the National Institutes of Health (NIH) fell by almost 20%. NIH is America's and the world's largest funder of basic medical research.*
- *During the above time period only one in five grant proposals received funding while at the same time the cost of conducting research (running labs, buying equipment, and paying researchers) rose.*
- *"To get a healthier citizenry, we've got to put research to work!"*

The realities and the hopes expressed in the above statements are ones that TBRI faces every day. While NIH's budget received a real boost from the federal economic stimulus package, competition for the increased funding is fierce. TBRI is working very diligently to access not only federal dollars but also resources from a wide range of public and private

contributors. That is where all of you come in. Keeping our doors open means having on-going support from our friends and donors. We cannot do it without you. Right now our research is at a critical juncture and private dollars can help bridge our current efforts to a point where we are in a more advantageous position for larger grant opportunities.

Last May the TBRI Board of Trustees made an all out strategic commitment to put in place a road map that will lead to on-going and sustainable funding for the Institute. As a result of a board retreat we have approved an exciting business plan for going forward and created an action plan to put in play the following five strategic priorities:

- *Increase our scientific programs*
- *Develop a national spokesperson and marketing campaign*
- *Increase and leverage Institute space*
- *Create new strategies for our traditional fund raising*
- *Create new strategies in the area of non-traditional fund raising*

Each of these priorities has a chair and committee members that come from our Board of Trustees. The Institute is extremely fortunate to have a committed, involved, and growing board. (See article about our latest members). We need all the assistance we can get from our friends and supporters in the TBRI community. We continue to be grateful for your on-going generosity. I look forward to seeing all of you at our Annual Community Reception on October 21.

In The Lab

with Dr. Guy Bradley

Much of our research has focused on the immune system and its relationship to cancer. There is also interesting research being conducted on allergies.

Estimates from a skin test survey suggest that allergies affect more than 50 million people in the United States. Allergy is the fifth leading chronic disease in the U.S. among all ages, and the third common chronic disease among children under 18 years old. The costs associated with allergic disease related primarily to lost work productivity are estimated to be about \$7.9 billion per year, of which \$4.5 billion is spent on direct care and \$3.4 billion on indirect costs. Allergies result in 2 million lost school days and 593 deaths (400 due to penicillin, 40 due to insect stings, 3 due to latex allergy, and 150 due to foods) each year.

WebMD defines allergies as an abnormal response of the immune system and states that people who have allergies have an immune system that reacts to a usually harmless substance in the environment. This substance (pollen, mold, animal dander, etc.) is called an allergen. Upon sensing the presence of an allergen, a set of white blood cells secrete antibodies to fend off or protect us from the allergen. The type of antibodies produced in response to the allergen are known as immunoglobulin E (IgE). Unfortunately for persons with allergies or asthma, the binding of IgE to the allergen results in the release of histamines and leukotrienes, the major mediators of allergy symptoms. Some of these allergic reactions can be so severe that anaphylaxis occurs and the person requires immediate emergency medical attention. This severe allergic reaction can occur in response to drugs (a response to penicillin is common), insect stings, food (peanut or seafood), and even latex.

There are currently three basic strategies used to treat and manage IgE-mediated allergies: avoidance, medication and immunotherapy (allergy shots). While avoidance sounds simple enough it often places a huge burden on the patient's personal and social activities, especially those with food allergies.

There are 3 major types of medications being used to treat the symptoms of allergies: antihistamines, steroids, and leukotriene modulators. Antihistamines are used broadly to treat symptoms of all kinds of allergic conditions and are available over-the-counter and by prescription. Steroids are sometimes used to treat moderate or severe allergic conditions and are only available by prescription. Steroids work by reducing inflammation. Leukotriene modifiers are long-term asthma control medications. They reduce swelling inside the airways and relax smooth muscles around the airways.

Allergy shots are a form of treatment called immunotherapy. Each injection contains a tiny amount of the allergen that triggers an allergic reaction. These injections contain just enough allergens to stimulate the immune system but not enough to cause a full-blown allergic reaction. Over time, the dose of allergen in the injections is increased to induce tolerance to the allergens. With this the allergy symptoms will diminish over time. Unfortunately, this might take upwards of 5 years to achieve.

The availability of a product that could reduce the symptoms of IgE mediated allergies, without exposing the patient to potentially serious side effects, would make a significant impact on the health and productivity of our citizens. Preliminary findings by the scientists at TBRI suggest that its patented extract might just be such a product. Our most recent findings are quite promising and have been submitted for publication in a peer-reviewed journal dedicated to publishing research associated with the development and use of complementary and alternative medicines. We will let you know when this article is published.




Introducing New Board Members

CARMINE LACOGNATA

Carmine LaCognata has been a financial professional since 1989 and has helped hundreds of individuals with their retirement funding and estate preservation planning. Mr. LaCognata is particularly knowledgeable at helping owners of closely held businesses protect their assets, provide cost-effective employee benefits and supplemental retirement plans.

Mr. LaCognata is responsible for managing the Central Florida Region of AXA Advisors, LLC, which includes 150 financial professionals and 23 Branch offices serving their communities.

His accreditations and professional affiliations are Executive Vice President, Southern Division Investment Advisory Representative, FINRA Series 65, Registered Representative, FINRA Series 6, 7, 63, Registered Principal, FINRA Series 24, 26, 53, and Financial Consultant of AXA Advisors, LLC.



JOHN KEARNEY

John Kearney was born in St. Petersburg, Florida and attended local schools as well as St. Petersburg Junior College. He graduated from the University of Florida with a Bachelor of Science in Business Administration in 1962 where he majored in Accounting and Economics. He became a Certified Public Accountant in 1964 and was a partner in the largest firm in the state of Florida.

Mr. Kearney is president of American Consulting Services Corp., a company that owns interests in the technical training field. He is Vice Chairman, President, Director and CEO of Career Path Training Corp. with offices in Texas, Florida, Utah, Indiana, Arkansas, Ohio, North Carolina, Tennessee, Oklahoma and Missouri. Career Path is also a developer of simulators for wheeled vehicles.

In addition, Mr. Kearney is the Chairman and President of The KML Foundation, and Chairman and President of the Krauss Miller Lutz Charitable Trust Foundation, Inc. These organizations make grants and scholarships to students for educational purposes. He is a member of the Board of Instructional Technologies, Inc., which is involved in the development and sale of training software.

Tampa Bay Research Institute Charitable Gift Annuity

WHAT IS A CHARITABLE GIFT ANNUITY?

A charitable gift annuity is a simple contract between you and TBRI. In exchange for your irrevocable gift of cash, securities, or other assets, TBRI agrees to pay one or two annuitants you name a fixed sum each year for life. The older your designated annuitants are at the time of the gift, the greater the fixed income TBRI can agree to pay. In most cases, part of each payment is tax-free, increasing each payment's after-tax value. Payments may be made annually, semiannually, or quarterly.

EXAMPLE:


If you irrevocably transfer \$25,000 in cash property to TBRI in exchange for a \$1,575 annuity for an annuitant, age 75,

BENEFITS INCLUDE:

- You will qualify for a federal income tax deduction of approximately \$11,220. Your deduction may vary modestly depending on the timing of your gift. Note that deductions for this and other gifts of cash and non-appreciated property will be limited to 50% of your adjusted gross income. You may, if necessary, take unused deductions of this kind over the next five years, subject to the same 50% limitation.
- Your designated annuitant will receive fixed payments in quarterly installments totaling \$1,575 each year for life. In addition, \$1,111.95 of each year's payments will be tax-free for the first 12.4 years.
- Your estate may enjoy reduced probate costs and estate taxes.
- You will provide generous support of TBRI.
- Sample rates: age 65: 5.3%; age 70: 5.7%; age 80: 7.1%; age 85: 8.1% Call TBRI for other age quotes.

These calculations are for illustration purposes only and should not be considered legal, accounting, or other professional advice. Your actual benefits may vary depending on the timing of the gift.

6.3% Charitable Gift Annuity



BENEFITS INCLUDE:

Immediate

Income tax deduction of \$11,220. May save up to \$3,927.

Annual

Annual Income of \$1,575 for life, \$1,112 tax free. Projected total after-tax income of \$16,955 over 12 years.

Future

TBRI projected to have \$25,869 in 12 years. May reduce estate taxes and costs.



CELL-ebrations of Life!!

Come one, come all! Plan on attending one of these quarterly presentations where we share the excitement and motivation behind what makes TBRI a life saving mission.

This one hour presentation is designed to introduce our progress, opportunities and challenges to bringing life saving research to the world.

Refreshments at 3:45. We start at 4 pm sharp.

November 18, 2009

February 17, 2010

May 19, 2010

August 18, 2010

Dates for one-on-one or small group presentations are available. Please call 727-576-6675 ext. 123 to RSVP or for more information.

www.tbri.org

www.tampabayresearch.org

727.576.6675

St. Petersburg, Florida 33716-2308

10900 Roosevelt Boulevard North



NON PROFIT
ORGANIZATION
U.S. POSTAGE
PAID
Permit # 2839
Tampa, Florida